中國生物製藥(01177.HK)在ASCO年會公布TQB2868聯合方案II期研究數據
中國生物製藥(01177.HK)公布,集團已在2025年美國臨床腫瘤學會(ASCO)年會公布TQB2868聯合安羅替尼與化療一線治療轉移性胰腺導管腺癌(mPDAC)的II期臨床研究初步數據。初步數據顯示:TQB2868聯合安羅替尼與AG化療的客觀緩解率達63.9%,為AG化療方案歷史數據的2-3倍;疾病控制率達100%,是AG化療方案的1.6倍;安全耐受性良好,3級及以上不良反應發生率為52.5%。
集團正在就TQB2868聯合方案的註冊III期臨床試驗與中國國家藥品監督管理局藥品審評中心進行溝通。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.